amantadine has been researched along with Atherosclerotic Parkinsonism in 62 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The administration of diuretics to a 64 year old patient with Parkinsonian disease treated by amantadine, orphenadrine and Modopart and presenting an oedemia of the legs, induced the apparition of myoclonic jerks similar to those observed in a bismuth intoxication." | 7.66 | [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)]. ( Brion, S; Chevalier, JF; Renier, E, 1980) |
| "The administration of diuretics to a 64 year old patient with Parkinsonian disease treated by amantadine, orphenadrine and Modopart and presenting an oedemia of the legs, induced the apparition of myoclonic jerks similar to those observed in a bismuth intoxication." | 3.66 | [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)]. ( Brion, S; Chevalier, JF; Renier, E, 1980) |
| "Amantadine and biperiden were equally effective in relieving neuroleptic-induced EPS and did not exacerbate TD-type movements." | 2.68 | No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. ( Geraisy, N; Schwartz, M; Silver, H, 1995) |
| "Bromocriptine appears to be an interesting development in the treatment of Parkinson's disease." | 2.64 | [Treatment of parkinsonian syndromes by bromocriptin]. ( Durand, JP; Gautier, JC, 1977) |
| "Amantadine is a putative dopaminergic compound known to be therapeutically effective in idiopathic and postencephalitic Parkinson's disease." | 2.64 | Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. ( Fann, WE; Lake, CR, 1976) |
| "There are many causes of parkinsonism such as drug induced parkinsonism, subcortical vascular disease, and multisystem atrophy." | 2.42 | [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]. ( Ceballos-Baumann, A, 2003) |
| " Acute dystonias consist of abnormal muscle spasms and postures and usually occur three to five days after antipsychotic therapy begins or the dosage is increased." | 2.40 | Management of acute extrapyramidal effects induced by antipsychotic drugs. ( Holloman, LC; Marder, SR, 1997) |
| "Amantadine is an evidence-based pharmacologic strategy for treating drug-induced parkinsonism and might be an alternative treatment for other DIMDs in select patients." | 1.56 | Revisiting amantadine as a treatment for drug-induced movement disorders. ( Caroff, SN; Jain, R; Morley, JF, 2020) |
| "The mice developed catalepsy after 3 weeks on the LCa/Mg diet." | 1.39 | Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. ( Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F, 2013) |
| "Pretreatment with hemantane (10 mg/kg) and the reference drug amantadine (20 mg/kg) 5 days before MPTP and further administration during 3 weeks after MPTP preserve cognitive function and prevented depressive disturbances in rats." | 1.38 | [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease]. ( Ivanova, EA; Kapitsa, IG; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2012) |
| "The diagnosis of patients 2 and 3 was vascular dementia with multiple subcortical ischemic lesions, and single photon emission CTs showed reduced cerebral blood flow in the frontal lobes." | 1.29 | [Improved perseveration with amantadine]. ( Imamura, T; Itoh, H; Itoh, M; Nagasawa, H; Sahara, M; Suzuki, K; Yamadori, A, 1994) |
| " An increase in dosage also had only a transient effect." | 1.27 | Development of tolerance to the therapeutic effect of amantadine on akathisia. ( Barreira, P; Lipinski, JF; Zubenko, GS, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (66.13) | 18.7374 |
| 1990's | 11 (17.74) | 18.2507 |
| 2000's | 4 (6.45) | 29.6817 |
| 2010's | 5 (8.06) | 24.3611 |
| 2020's | 1 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Caroff, SN | 1 |
| Jain, R | 1 |
| Morley, JF | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Cheung, YF | 1 |
| Hui, CH | 1 |
| Chan, JH | 1 |
| Bido, S | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Nepoklonov, AV | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Taniguchi, R | 1 |
| Nakagawasai, O | 1 |
| Tan-no, K | 1 |
| Yamadera, F | 1 |
| Nemoto, W | 1 |
| Sato, S | 1 |
| Yaoita, F | 1 |
| Tadano, T | 1 |
| Takahashi, H | 1 |
| Shinohara, Y | 1 |
| Ceballos-Baumann, A | 1 |
| Bibbiani, F | 1 |
| Oh, JD | 1 |
| Kielaite, A | 1 |
| Collins, MA | 1 |
| Smith, C | 1 |
| Chase, TN | 2 |
| Borison, RL | 1 |
| Zubenko, GS | 1 |
| Barreira, P | 1 |
| Lipinski, JF | 1 |
| Gómez, EA | 1 |
| Schunk, W | 1 |
| Danielczyk, W | 1 |
| Chevalier, JF | 1 |
| Renier, E | 1 |
| Brion, S | 1 |
| Lechner, H | 1 |
| Bertha, G | 1 |
| Ott, E | 1 |
| Altagracia, M | 2 |
| Rojas, P | 2 |
| Kravzov, J | 1 |
| Rios, C | 2 |
| Silver, H | 1 |
| Geraisy, N | 1 |
| Schwartz, M | 1 |
| Imamura, T | 1 |
| Suzuki, K | 1 |
| Yamadori, A | 1 |
| Sahara, M | 1 |
| Nagasawa, H | 1 |
| Itoh, M | 1 |
| Itoh, H | 1 |
| Edby, K | 1 |
| Larsson, J | 1 |
| Eek, M | 1 |
| von Wendt, L | 1 |
| Ostergård, B | 1 |
| Danysz, W | 1 |
| Parsons, CG | 1 |
| Kornhuber, J | 1 |
| Schmidt, WJ | 1 |
| Quack, G | 1 |
| Holloman, LC | 1 |
| Marder, SR | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Ahlskog, JE | 1 |
| Scarmeas, N | 1 |
| Eidelberg, D | 1 |
| Frucht, SJ | 1 |
| Scarmato, N | 1 |
| Mindham, RH | 2 |
| Kaumeier, S | 1 |
| Gautier, JC | 1 |
| Durand, JP | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Jacobi, P | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Pacifici, GM | 1 |
| Nardini, M | 1 |
| Ferrari, P | 1 |
| Latini, R | 1 |
| Fieschi, C | 1 |
| Morselli, PL | 1 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Cerone, G | 1 |
| Ruggieri, S | 1 |
| Aloisi, P | 1 |
| Cappenberg, L | 1 |
| Agnoli, A | 1 |
| Miras Portugal, MT | 1 |
| Aunis, D | 1 |
| Mandel, P | 1 |
| Warter, JM | 1 |
| Coquillat, G | 1 |
| Collard, M | 1 |
| Rohmer, F | 1 |
| Kadykov, AS | 1 |
| Dolezalová, B | 1 |
| Vacek, J | 1 |
| Evtushenko, SK | 1 |
| Kandel', EI | 1 |
| Iadgarov, IS | 1 |
| Völler, GW | 1 |
| Schubert, U | 1 |
| Fischer, GJ | 1 |
| Glass, J | 1 |
| Vardi, J | 1 |
| Streifler, M | 1 |
| Godwin-Austen, R | 1 |
| Kravsov, J | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Riederer, P | 1 |
| Weiser, M | 1 |
| Rabey, JM | 1 |
| Oberman, Z | 1 |
| Scharf, M | 1 |
| Isakov, M | 1 |
| Bar, M | 1 |
| Graff, E | 1 |
| Keepers, GA | 1 |
| Casey, DE | 1 |
| Fayen, M | 1 |
| Goldman, MB | 1 |
| Moulthrop, MA | 1 |
| Luchins, DJ | 1 |
| Lieberman, AN | 1 |
| Rüther, E | 1 |
| Fussmann-Hegewald, M | 1 |
| Eben, E | 1 |
| Kamianov, IM | 1 |
| Kupisk, AG | 1 |
| Katsen, IZ | 1 |
| Rappaport, M | 1 |
| Velkov, VA | 1 |
| Shimomura, SK | 1 |
| Balunov, OA | 1 |
| Bazhin, EF | 1 |
| Morozova, ES | 1 |
| Fedotenkova, TN | 1 |
| Boczán, G | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Kelly, JT | 1 |
| Zimmermann, RL | 1 |
| Abuzzahab, FS | 1 |
| Schiele, BC | 1 |
| Kiseleva, AM | 1 |
| Zlydnikov, DM | 1 |
| Mazhinskaia, VP | 1 |
| Lebedeva, VK | 1 |
| Zakharova, NG | 1 |
| Cincă, I | 1 |
| Bulandra, R | 1 |
| Serbănesco, A | 1 |
| Ninosu, N | 1 |
| Albert, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.[NCT00632762] | Phase 4 | 80 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for amantadine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
[Diagnosis and therapy for patients with vascular parkinsonism].
Topics: Akinetic Mutism; Amantadine; Antiparkinson Agents; Cerebral Infarction; Dementia, Vascular; Diagnosi | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inh | 2003 |
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Topics: Amantadine; Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Memantine; Parkinson D | 1997 |
Management of acute extrapyramidal effects induced by antipsychotic drugs.
Topics: Adrenergic beta-Antagonists; Akathisia, Drug-Induced; Amantadine; Antipsychotic Agents; Benzodiazepi | 1997 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; | 1999 |
[Progress in therapy of Parkinsonian syndrome].
Topics: Amantadine; Carboxy-Lyases; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parasymp | 1975 |
Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Amantadine; Antipsychotic Ag | 1986 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; D | 1971 |
10 trials available for amantadine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Antipsychotic Agents; Biperiden; Cross-Over Studies; Double-Blind Method; Dyskine | 1995 |
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Human | 1977 |
Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.
Topics: Amantadine; Clinical Trials as Topic; Humans; Parkinson Disease, Secondary; Tranquilizing Agents; Tr | 1976 |
Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.
Topics: Adult; Amantadine; Biological Availability; Clinical Trials as Topic; Female; Half-Life; Humans; Mid | 1976 |
[Treatment of Parkinsonian syndrome using amantadine hydrochloride].
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Electrom | 1975 |
Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
Topics: Adult; Amantadine; Antipsychotic Agents; Cerebral Ventricles; Clinical Trials as Topic; Dilatation, | 1988 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Benztropine; Capsules; Chlorpromazine; Clini | 1974 |
[The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
Topics: Adult; Aged; Amantadine; Chronic Disease; Female; Humans; Male; Middle Aged; Parasympatholytics; Par | 1973 |
44 other studies available for amantadine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Revisiting amantadine as a treatment for drug-induced movement disorders.
Topics: Amantadine; Antiparkinson Agents; Humans; Parkinson Disease, Secondary | 2020 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
Parkinsonism-hyperpyrexia syndrome due to abrupt withdrawal of amantadine.
Topics: Amantadine; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2012 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine | 2013 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease | 2005 |
Amantadine in the management of extrapyramidal side effects.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Humans | 1983 |
Development of tolerance to the therapeutic effect of amantadine on akathisia.
Topics: Adult; Akathisia, Drug-Induced; Amantadine; Bipolar Disorder; Drug Tolerance; Female; Haloperidol; H | 1984 |
[Extrapyramidal reactions and neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Basal Ganglia Diseases; Dantrolene; Haloperidol; Humans; Male; Neuroleptic Malign | 1984 |
[New aspects of chronic occupational manganese poisoning].
Topics: Amantadine; Diagnosis, Differential; Humans; Levodopa; Manganese Poisoning; Occupational Diseases; P | 1982 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson | 1980 |
[Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)].
Topics: Amantadine; Diuretics; Drug Interactions; Drug Therapy, Combination; Edema; Humans; Male; Middle Age | 1980 |
[Current treatment of Parkinsonian syndrome].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease, Secondary | 1980 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
[Improved perseveration with amantadine].
Topics: Aged; Amantadine; Aphasia; Dementia, Vascular; Dopamine; Encephalitis; Female; Humans; Magnetic Reso | 1994 |
Amantadine treatment of a patient with anoxic brain injury.
Topics: Activities of Daily Living; Adolescent; Amantadine; Antiparkinson Agents; Brain Damage, Chronic; Bra | 1995 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Brain Ischemia; Diagnosis, Differe | 2001 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Mid | 1978 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug | 1977 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
[Pharmacological study of parkinsonian tremor. II. Role of the dopamine-acetylcholine system].
Topics: Acetylcholine; Aged; Amantadine; Brain; Dopamine; Female; Humans; Male; Middle Aged; Parasympatholyt | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disord | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Di | 1976 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combina | 1976 |
[Catecholamine excretion and treatment of parkinsonism with midantan].
Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Huma | 1976 |
On the synchronizing effect of amantadine-1-hydrochlorid (Symmetrel) on pathological EEG-activity.
Topics: Amantadine; Brain; Cortical Synchronization; Electroencephalography; Female; Humans; Middle Aged; Ne | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Corpus Striatum; Dopamine; Homova | 1992 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; | 1990 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
The effect of amantadine on neuroleptic-induced parkinsonism.
Topics: Adult; Amantadine; Antipsychotic Agents; Butyrophenones; Female; Humans; Male; Middle Aged; Parkinso | 1973 |
[Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Catatonia; Chlorpromazine; Facial Mus | 1973 |
Mental health research at a state hospital. An attempt at a balanced program.
Topics: Amantadine; Attitude of Health Personnel; Auditory Perception; Behavior Therapy; Computers; Conditio | 1968 |
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amantadine; Animals; Brain; Brain Chemistry; Dise | 1974 |
Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson | 1972 |
[Use of the Soviet preparation midantan in the treatment of the Parkinsonian syndrome].
Topics: Adult; Aged; Amantadine; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle | 1974 |
Effect of amantadine (Viregyt-K) on extrapyramidal symptoms of parkinsonian patients.
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Drug Administration Schedule; Extrapyramidal Tracts | 1974 |
[Current medical treatment of Parkinsonian syndromes].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Combination | 1973 |
Treatment for Parkinsonism, other than levodopa.
Topics: Amantadine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1972 |
Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
Topics: Amantadine; Diagnosis, Differential; Dihydroxyphenylalanine; Humans; Hyperkinesis; Movement Disorder | 1971 |